Khandelwal, Shweta; Swamy, MK; Patil, Kamal; Kondal, Dimple; Chaudhry, Monica; Gupta, Ruby; Divan, Gauri; Kamate, Mahesh; Ramakrishnan, Lakshmy; Bellad, Mrutyunjaya B; +8 more... Gan, Anita; Kodkany, Bhalchandra S; Martorell, Reynaldo; Srinath Reddy, K; Prabhakaran, Dorairaj; Ramakrishnan, Usha; Tandon, Nikhil; Stein, Aryeh D; (2018) The impact of DocosaHexaenoic Acid supplementation during pregnancy and lactation on Neurodevelopment of the offspring in India (DHANI): trial protocol. BMC PEDIATRICS, 18 (1). 261-. ISSN 1471-2431 DOI: https://doi.org/10.1186/s12887-018-1225-5

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4651396/

DOI: https://doi.org/10.1186/s12887-018-1225-5

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
The impact of DocosaHexaenoic Acid supplementation during pregnancy and lactation on Neurodevelopment of the offspring in India (DHANI): trial protocol

Shweta Khandelwal1,2*, M. K. Swamy3, Kamal Patil3, Dimple Kondal1, Monica Chaudhry1, Ruby Gupta1, Gauri Divan4, Mahesh Kamate5, Lakshmy Ramakrishnan6, Mrutyunjaya B. Bellad7, Anita Gan3, Bhalchandra S. Kodkany7, Reynaldo Martorell8, K. Srinath Reddy1, Dorairaj Prabhakaran1,2, Usha Ramakrishnan8, Nikhil Tandon6 and Aryeh D. Stein8

Abstract

Background: Evidence suggests a strong association between nutrition during the first 1000 days (conception to 2 years of life) and cognitive development. Maternal docosahexaenoic acid (DHA) supplementation has been suggested to be linked with cognitive development of their offspring. DHA is a structural component of human brain and retina, and can be derived from marine algae, fatty fish and marine oils. Since Indian diets are largely devoid of such products, plasma DHA levels are low. We are testing the effect of pre- and post-natal DHA maternal supplementation in India on infant motor and mental development, anthropometry and morbidity patterns.

Methods: DHANI is a double-blinded, parallel group, randomized, placebo controlled trial supplementing 957 pregnant women aged 18–35 years from ≤ 20 weeks gestation through 6 months postpartum with 400 mg/d algal-derived DHA or placebo. Data on the participant’s socio-demographic profile, anthropometric measurements and dietary intake are being recorded at baseline. The mother-infant dyads are followed through age 12 months. The primary outcome variable is infant motor and mental development quotient at 12 months of age evaluated by Development Assessment Scale in Indian Infants (DASII). Secondary outcomes are gestational age, APGAR scores, and infant anthropometry. Biochemical indices (blood and breast-milk) from mother-child dyads are being collected to estimate changes in DHA levels in response to supplementation.

All analyses will follow the intent-to-treat principle. Two-sample t test will be used to test unadjusted difference in mean DASII score between placebo and DHA group. Adjusted analyses will be performed using multiple linear regression.

Discussion: Implications for maternal and child health and nutrition in India: DHANI is the first large pre- and post-natal maternal dietary supplementation trial in India. If the trial finds substantial benefit, it can serve as a learning to scale up the DHA intervention in the country.

Trial registration: The trial is retrospectively registered at clinicaltrials.gov (NCT01580345, NCT03072277) and ctril.nic.in (CTRI/2013/04/003540, CTRI/2017/08/009296).

Keywords: Docosahexaenoic acid (DHA), Omega 3 fatty acids, Polyunsaturated fatty acids, n3PUFA, Neurodevelopment, Development assessment scale for Indian infants (DASII), Maternal supplementation, Pregnancy outcomes, Newborn outcomes
Background

The period from conception through to a child’s second birthday, commonly referred to as ‘the first 1000 days,’ is a crucial window to improve maternal child health and nutrition indicators and optimize human capital [1, 2]. The brain develops rapidly through neurogenesis, axonal and dendritic growth, synaptogenesis, cell death, synaptic pruning, myelination, and gliogenesis [3–5]. These ontogenetic events build on each other, such that even small perturbations can have long-term effects on the brain’s structural and functional capacity [6]. A mother’s nutrition during this critical phase impacts both prenatal and postnatal growth and the development of offspring [7, 8]. Higher omega 3 long chain polyunsaturated fatty acid (n-3 LCPUFA) levels such as docosahexaenoic acid (DHA) have been associated with enhanced infant neurodevelopment [9–16].

DHA is an important structural component of human brain and retina. It can be obtained from marine algae, fatty fish and marine oils. Since Indian diets are largely deficient in DHA-rich sources, the population levels of plasma DHA are quite low [17, 18]. Indians do consume sources of the precursor, alpha-linolenic acid (ALNA 18:3n-3; a short-chain omega-3 fatty acid) like mustard oil, soybean oil, flaxseeds, walnuts. However, excess omega-6 fats in Indian diets inhibit the endogenous synthesis of DHA from ALNA [19]. Thus, negligible DHA-rich products coupled with an excess of omega-6 sources result in low plasma DHA and a sub-optimal omega-3 to omega-6 ratio among Indian populations [20, 21]. The ideal ratio of omega-3 to omega-6 should be 1:1 to 1:2.5. However, in Indian diets it is usually around 1:17 to 1:20 [22, 23]. These low levels become a concern especially during peak spurts of neurodevelopment such as the first 1000 days [24].

DHA and neurodevelopment

Long chain polyunsaturated fatty acids, particularly DHA (22:6n-3) and arachidonic acid (20:4n-6), are integral to fetal, neural and retinal development and accrete extensively in the last trimester of pregnancy [25]. Despite the implications for child development, there have been few studies which have comprehensively tested interventions in humans. Makrides et al. showed that high-DHA (approximately 1% total fatty acids) enteral feeds compared with standard DHA (approximately 0.3% total fatty acids) from day 2 to 4 of postnatal life showed significantly higher (unadjusted mean difference, 4.7; 95% CI, 0.5–8.8; adjusted mean difference, 4.5; 95% CI, 0.5–8.5) Bayley’s Mental Development Index scores in Australian girls, however among the boys, it did not differ between groups [26, 27]. Ramakrishnan et al. [28] summarized studies in this area and reported that observational studies indicated a direct association between poor n-3 fatty acid status and increased risk of maternal depression and childhood behavioral disorders such as attention-deficit hyperactivity disorder (ADHD). It has also been hypothesized that prenatal exposure to DHA may also affect later development through fetal programming of the central nervous system and various other physiologic pathways. Ramakrishnan et al. in 2016 reported a beneficial impact of prenatal DHA supplementation on attention in preschoolers at 5 years of age where DHA group children recorded significantly fewer omissions (<40) as compared to the control group on K-CPT (Conners’ Kiddie Continuous Performance Test). Also, the magnitude of positive association between home stimulation and cognitive functioning was found to be less in the DHA group (b = 0.71; 95% CI: 0.13, 1.29; placebo group: b = 1.71; 95% CI: 1.09), [29]. Another randomized trial, the DHA Intake and Measurement of Neural Development (DIAMOND) study [16] suggested some benefit of DHA supplementation of infants form 1–9 days of age till 12 months on visual acuity of infants at 1 year of age. It was observed that infants fed with control formula had significantly poorer visual acuity than the infants who were fed with DHA-supplemented formulas (P < 0.001). Evidence for association between increased consumption of sea food in pregnancy and improved neurodevelopmental outcomes in their children have also been shown in observational studies [30–33]. However, evidence from intervention trials from low- and middle-income settings is scanty. Most of the studies reviewed were conducted in developed countries. Some trials had small sample sizes too. Thus large, well-designed, community-based prevention trials from developing countries are warranted.

In summary, studies conducted to date suggest that improvements in DHA levels in mother may confer some benefit for child neurodevelopment. Furthermore, DHA appears to be safe, with no adverse birth outcomes related to DHA supplementation observed in low-risk pregnancy cases [34]. Very few studies to date have continued supplementation through lactation. We therefore implemented a large scale randomized trial to study the effects of pre- and post-natal DHA supplementation on birth weight, gestational age and neurodevelopment in India, a country with low DHA intakes and a high dietary n-6 to n-3 ratio. This will be the first to examine the effects of in-utero and early life DHA exposure (through maternal supplementation from mid-pregnancy through 6 months postpartum) on postnatal neurodevelopment and body-size of Indian infants. Long term contact and follow-up with this cohort is being planned. The biological specimens being collected (blood, cord-blood, and breast-milk) from the mother-child dyads can further help pursue new hypotheses and unravel critical information about early DHA intervention on later life of an individual [35–41].
Methods

Study design
DocosaHexaenoic Acid supplementation during pregnancy and lactation on Neurodevelopment of the offspring in India (DHANI) is a double-blinded, randomized, placebo controlled trial being conducted in India. Study participants are healthy pregnant women and their offsprings.

DHANI will assess the impact of 400 mg of pre- and post-natal DHA supplementation (from ≤20 weeks of gestation to 6 months postpartum) on infant neurodevelopment at 6 and 12 months as measured by the Development Assessment Scale for Indian Infants (DASII). Secondary objectives of this trial include an assessment of the impact of maternal DHA supplementation on: gestational age, new born anthropometry (birth weight, length and head circumference) and APGAR score; infant anthropometry (birth weight, length and head circumference) at birth, 1 month, 6 months and 12 months; number of unfavorable pregnancy outcomes (still births, low birth weight babies, preterm babies); morbidity patterns through 12 months in the two groups. The first mother was enrolled on 6 Jan 2016 and the last on 31st Aug 2017. The data being collected under the trial for mother-infant dyads at each time point has been presented in Table 1.

Study population
The study population consists of 18–35 year old women with singleton pregnancy of ≤20 weeks of gestational age registered at the Obstetrics and Gynaecology outpatient department (OBGYN OPD), Prabhakar Kore hospital (PKH) for antenatal check-up. The PKH under KLE University’s Jawaharlal Nehru Medical College (JNMC) in Belgaum, Karnataka, India caters to the local population and the villages in and around Belgaum. PKH reports nearly 500–600 deliveries per month. Detailed inclusion and exclusion criteria are provided in Table 2.

Exposure
The exposure is 400 mg of algal DHA to be consumed daily by pregnant women from ≤20 weeks of gestation until 6 months postpartum recruited under the trial. The study staff delivers a bottle with 35 capsules (2 capsules per day X 15 day + 5 extra for spillage, spoilage, etc..) which match the allotted code of the subject. The bottles are either collected by the participant every fortnight or distributed by study personnel during fortnightly visits at the participant's home or workplace. The women are instructed to take two capsules daily, preferably at the same time each day.

Control
The control is a placebo which contains 200 mg per capsule of corn/soy oil (both active and placebo capsules provide the same, but negligible, energy). The placebo capsules provide no DHA and a negligible amount of omega-6 fatty acids. The active and placebo capsules are identical with respect to taste and appearance and only differ in coding.

Outcomes

Primary outcome
- Mean difference in the infant neurodevelopmental score (DQ), motor score and mental scores, as measured by the DASII scale 12 months.

Secondary outcome(s)
- Difference in proportions of infants with developmental delay between the DHA and placebo group at 12 months. Developmental delay will be defined as a DASII score ≤70.
- Mean difference in infant size (weight, length and head circumference) and APGAR score at birth.
- Mean change in infant size (weight, length and head circumference) at birth, 1 month, 6 months and 12 months between the DHA and placebo group.
- Mean difference in number of still births, preterm and low birth weight babies between DHA and placebo groups.
- Difference in infant morbidity patterns (types of illness, frequency and duration of specific conditions) between DHA and placebo group.

Tertiary outcomes
- Difference in DHA values (as measured by fatty acids in maternal blood) from baseline to delivery and 6 months post-partum in the two treatment groups.
- Difference in DHA values (as measured by fatty acids in cord blood and breast milk) in the two treatment groups.

Ethical approvals
Ethical clearances were obtained from all participating institutions including: Chronic Disease Control (CCDC-IEC-04_2015), Public Health Foundation of India (TRC-IEC-261/15), Jawaharlal Nehru Medical College (MDC/IECHSR/2016–17/A-85) and All India Institute of Medical Sciences (IEC-28/17.11.2015). The trial is registered retrospectively at the clinicaltrials.gov (NCT 01580345, NCT03072277) and ctr.nic.in (CTRI/2013/04/003540, CTRI/2017/08/009296). Trial registration was completed after participant recruited had started. An independent Data and Safety Monitoring Board (DSMB) was constituted before the start of the trial to review the study data periodically to monitor safety and outcomes.

Effect size, power and sample size
The primary outcome variables are infant motor and mental development quotient at 12 months of age. The smallest effect sizes of interest were 0.25 S.D. for motor...
| Domain                      | Measure                                | Data obtained on woman | Data obtained on child |
|-----------------------------|----------------------------------------|------------------------|------------------------|
| Pregnancy                  | Enrolment at ≤20 weeks                 |                        |                        |
|                             | Each month until Delivery              |                        | Birth                  |
|                             | Delivery                               |                        | 6 months               |
| Medical and Obstetric History | Clinical Investigation                | X                      | X                      |
|                             | Obstetric History                      | X                      |                        |
|                             | Complications                          | X                      | X                      |
|                             | Adverse events                         | X                      | X                      |
|                             | Eligibility                            | X                      | X                      |
| Blood                      | Fatty acid composition                 | X                      | X                      |
| Breast milk (30%)          | Fatty acid composition                 |                        | X                      |
| Body Size & composition    | Anthropometry (weight, length, mid upper arm circumference, head circumference of offspring) | X                      | X                      |
| Behavioral Factors         | Dietary Intake                         |                        |                        |
|                             | Physical activity                      | X                      |                        |
|                             | Prenatal Care                          | X                      |                        |
|                             | Substance use                          | X                      |                        |
| Child development          | APGAR                                  | X                      |                        |
|                             | Developmental Quotient                 |                        | X                      |
|                             | Morbidity                              |                        | X                      |
and mental development at 12 months of age [42]. Using a two-tailed test and a significance level of \(\alpha = 0.05\), a final sample of 338 infants per group (676 mother-child dyads) was required at the end of the study (12 months postpartum) to provide 90% power. A total of 957 mothers have been recruited in the present study, allowing for potential attrition due to serious adverse events, withdrawal, and migration out of the study area. Breast-milk samples are being collected within 3–4 days after delivery and at 1 month and 6 months postpartum from a 30% convenience sub-sample - 150 mother-infant pairs per group, which will have 95% power to detect effect sizes of 0.5 S.D. in DHA levels.

**Recruitment**

The pregnant women were screened by the project officer with the help of the attending medical doctor to verify eligibility. A project officer then explained the study in detail and invited the eligible candidate for participation. Written informed consent was provided by all willing participants in presence of a family member. The copy of the informed consent and subject information sheet were provided in their preferred local language (Kannada, Marathi or Hindi).

**Randomization procedure**

Consenting women were randomized to their treatment group by the project officer. The randomization scheme consisted of a sequence of blocks such that each block contained a pre-specified number of treatment assignments in random order. The block size of 2, 4 and 6 was used for treatment allocation. The randomization code list was pre-generated for 1200 women randomly allocating 600 participants to the DHA and 600 participants to placebo group. The assignment codes were placed in sealed envelopes at the beginning of the study, and these envelopes were kept sealed at the host institution by a staff-member not involved in the trial.

**Data collection**

- Primary outcome variable: The development quotient (DQ) among infants at 12 months of age assessed using the standardized DASII scale [43, 44] by two trained psychologists is the primary outcome variable [45, 46]. DASII is the Indian modification (done in 1970 and 1977) of the Bayley Scale of Infant Development (BSID) using Indian norms for 67 motor and 163 mental items of the BSID. DASII provides a measure of DQ among Indian infants below 30 months of age [47, 48]. DQ is defined as the ratio of functional to chronological age. Third, 50th and 97th percentile norms are given. The maximum DQ score is 100; \(\geq 85\) is normal; 71–84 is mild to moderate delay and developmental delay is defined as DQ \(\leq 70\) (\(\leq 2SD\)). Median reliability index for motor and mental scales based on correlation between consecutive months is noted to be 0.88 for motor scales and 0.91 for mental scales. The motor development items cover the child’s development from supine to erect posture, neck-control, locomotion etc. It also includes the record for manipulative behaviour such as reaching, picking-up, handling things etc. The mental development items record the child’s cognizance of objects in the surroundings, perceptual pursuit of moving objects, exploring them to meaningful manipulation. It also covers the development of communication and language comprehension, spatial relationship and manual dexterity, imitative behavior and social interaction etc. Each child undergoes DASII assessment twice – once at 6 months and again at 12 months. For infants born preterm, the assessment is done at their corrected ages of 6 and 12 months.

- Secondary outcomes:
- Birth outcomes – Data are collected by a research assistant from hospital records within 24 h after delivery. In case of night deliveries, records from hospital staff are obtained the next morning. All hospital staff were apprised of the variables being collected, procedures and data collection methods before the start of the trial. A periodic (every 6 months) refresher training has also been provided to the staff. The data include whether the birth was

**Table 2** Inclusion and Exclusion Criteria for DHANI trial

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| Pregnant woman aged 18 years to 35 years (singleton) at \(\leq 20\) weeks of gestation (calculated from the last menstrual period or by ultrasound in 1st trimester as suggested by study physician/team). | Women with high-risk pregnancies or bad obstetric history |
| Willing to participate in the study and provide all measurement for self, husband and the offspring including anthropometry, dietary assessment and questionnaire plus the biological samples (blood, breast milk) | Women allergic (if aware) to any of the test products |
| Plans to deliver at the study hospital | Women consuming omega-3/DHA supplements or having used these in 3 months preceding the intervention period |
| Willing to comply with study specific procedure/instruction | Participated in another drug trial within or before 3 months from the date of screening under this study or during the study |
| Consenting women were randomized to their treatment | Women allergic (if aware) to any of the test products |
| The pregnant women were screened by the project officer with the help of the attending medical doctor to verify eligibility. A project officer then explained the study in detail and invited the eligible candidate for participation. Written informed consent was provided by all willing participants in presence of a family member. The copy of the informed consent and subject information sheet were provided in their preferred local language (Kannada, Marathi or Hindi). | Women with chronic conditions like Hypertension, heart disease, Cancer, Diabetes, epilepsy, liver disorders, thyroid problem, known history of bleeding disorders or thrombosis or any other medical condition which may affect the safety of mother/infant in opinion of study investigator/physician. |
| Consent and subject information sheet were provided in | Women consuming omega-3/DHA supplements or having used these in 3 months preceding the intervention period |
| Breast-milk samples are being collected within 3–4 days after delivery and at 1 month and 6 months postpartum from a 30% convenience sub-sample - 150 mother-infant pairs per group, which will have 95% power to detect effect sizes of 0.5 S.D. in DHA levels. | Participated in another trial in the past |
| The pregnant women were screened by the project officer with the help of the attending medical doctor to verify eligibility. A project officer then explained the study in detail and invited the eligible candidate for participation. Written informed consent was provided by all willing participants in presence of a family member. The copy of the informed consent and subject information sheet were provided in their preferred local language (Kannada, Marathi or Hindi). | Women allergic (if aware) to any of the test products |
| Consent and subject information sheet were provided in | Women consuming omega-3/DHA supplements or having used these in 3 months preceding the intervention period |
| Breast-milk samples are being collected within 3–4 days after delivery and at 1 month and 6 months postpartum from a 30% convenience sub-sample - 150 mother-infant pairs per group, which will have 95% power to detect effect sizes of 0.5 S.D. in DHA levels. | Participated in another drug trial within or before 3 months from the date of screening under this study or during the study |

**Randomization procedure**

Consenting women were randomized to their treatment group by the project officer. The randomization scheme consisted of a sequence of blocks such that each block contained a pre-specified number of treatment assignments in random order. The block size of 2, 4 and 6 was used for treatment allocation. The randomization code list was pre-generated for 1200 women randomly allocating 600 participants to the DHA and 600 participants to placebo group. The assignment codes were placed in sealed envelopes at the beginning of the study, and these envelopes were kept sealed at the host institution by a staff-member not involved in the trial.

**Data collection**

- Primary outcome variable: The development quotient (DQ) among infants at 12 months of age assessed using the standardized DASII scale [43, 44] by two trained psychologists is the primary outcome variable [45, 46]. DASII is the Indian modification (done in 1970 and 1977) of the Bayley Scale of Infant Development (BSID) using Indian norms for 67 motor and 163 mental items of the BSID. DASII provides a measure of DQ among Indian infants below 30 months of age [47, 48]. DQ is defined as the ratio of functional to chronological age. Third, 50th and 97th percentile norms are given. The maximum DQ score is 100; \(\geq 85\) is normal; 71–84 is mild to moderate delay and developmental delay is defined as DQ \(\leq 70\) (\(\leq 2SD\)). Median reliability index for motor and mental scales based on correlation between consecutive months is noted to be 0.88 for motor scales and 0.91 for mental scales. The motor development items cover the child’s development from supine to erect posture, neck-control, locomotion etc. It also includes the record for manipulative behaviour such as reaching, picking-up, handling things etc. The mental development items record the child’s cognizance of objects in the surroundings, perceptual pursuit of moving objects, exploring them to meaningful manipulation. It also covers the development of communication and language comprehension, spatial relationship and manual dexterity, imitative behavior and social interaction etc. Each child undergoes DASII assessment twice – once at 6 months and again at 12 months. For infants born preterm, the assessment is done at their corrected ages of 6 and 12 months.

- Secondary outcomes:
- Birth outcomes – Data are collected by a research assistant from hospital records within 24 h after delivery. In case of night deliveries, records from hospital staff are obtained the next morning. All hospital staff were apprised of the variables being collected, procedures and data collection methods before the start of the trial. A periodic (every 6 months) refresher training has also been provided to the staff. The data include whether the birth was
and subjected to gas chromatography (GC) for further analysis. Lipids will be extracted from red blood cells (RBCs) to measure their concentration. The fatty acid profiles of the red blood cells will be separated by thin layer chromatography (TLC), ensuring their accuracy.

- **Fatty acid profile:** The fatty acid composition of red blood cell membranes will be determined as phospholipids. This measurement reflects dietary intakes of fatty acids and is used to establish biomarkers of fatty acid status, thereby indicating dietary intake levels.

- **Breast milk polyunsaturated fatty acids (PUFAs):** Breast milk samples collected at different stages after delivery will be analyzed for their polyunsaturated fatty acid content, which can be a useful indicator of maternal diet intake.

**Training of staff and calibration of equipment**

The DHANI trial's personnel were recruited from local areas and trained before the start of the trial. The training included computer literacy, data collection methods, and food frequency questionnaire (FFQ) distribution. The data was collected using a validated FFQ, and the personnel for the trial were recruited from the local areas.

**Database and data management**

The database was developed using Microsoft Access on a desktop application, ensuring the system's compliance with CFR Part 11 standards. The database included an inbuilt audit trail function and was designed to record details of users who access the database. Data was scanned and analyzed centrally at the beginning of the trial.
Study intervention
The test supplements were capsules with either algal DHA or placebo (soy/corn oil in 50:50 ratio). Each DHA capsule contains 200 mg of DHA derived from an algal source. The placebo capsules contained an equal amount of corn/soy oil. All participating women received either 2 placebo or DHA capsules from ≤20 weeks of gestation until 6 months postpartum. The total dosage of DHA being given via active capsules was 400 mg/d (2 x 200 mg). The active and placebo capsules used were identical with respect to taste and appearance and only differed in coding.

Manufacture
Identical capsules for the intervention and control groups were provided by DSM Nutritional Products, Mumbai. They were received by the bottling vendor who packaged the batch into white opaque bottles with 15 days supply (30 plus 5 extra for spillage = 35) in each. These bottles were coded by the bottling warehouse by staff not involved directly in the study. The supplements were then couriered to the site and provided to women by trained field-workers during fortnightly visits at the participant’s home or workplace. The shelf life of each batch of capsules is close to 2 years at room temperature (25 °C).

Administration
A fortnightly schedule was drawn up for each woman from the day of her randomization. Supplements were provided by field workers during home visits. If informed about travel plans by the participant, study staff provided more than 1 bottle at a time. The women were instructed to take two capsules daily, preferably, at the same time each day. All the women also received iron-folic acid tablets for 100 days as per the Government of India policy.

Monitoring adherence
Compliance for each woman was recorded in a basic form (15 days record) in which the participant marked with a tick if she consumed the capsule. In case she expressed any difficulties completing the form, the FW followed up by asking her details during home visits. The 2 weeks’ record along with the left over/unused capsules in the bottle of the supplements was collected by field workers from the participants' home. During the home visit, the field worker also recorded details of any side effects, adverse event or illness and capsule count in a follow-up record form (Compliance Form). Weekly reminder phone calls were done for each mother by study personnel. Compliance is calculated as the total number of capsules actually consumed, expressed as a percentage of the total number expected to be consumed.

Blinding
All study participants and members of the study team were blinded to the treatment scheme throughout the intervention period of the study. Data will be unblinded for the analytical study team after the last baby born in the study turns 1 year of age. Since the study may be extended for follow-up of child development, participants and field personnel will remain blinded to the treatment allocation.

Emergency unblinding
Unblinding will only be performed if the number of serious adverse events (SAEs) observed during the trial is significantly higher in one group than the other. The final discretion to make this call will that be of the DSMB.

Reporting of adverse events
Adverse events (AEs) or SAEs (hospital admission, maternal or fetal or child death, abortion placenta, congenital anomaly, any other medically significant event) are reported as soon as (within 24 h of knowing) possible by the project officer to the study physician, who in turn examines and notifies the site principal investigator about the nature and severity of the AE. The study’s site principal Investigator (PI) notifies all serious AEs within 24 h to the trial Principal Investigator, Institutional Review Boards (IRBs). The DSMB is also notified each time. A summary quarterly report to DSMB and annual report to the ethics committees is also being submitted for their perusal. Table 3 lists the expected AEs and SAEs.

Compensation
Clinical trial insurance has been procured to compensate clinical trial participants where required (Policy Number OG-17-1401-3306-0000001). Also, the participants are being compensated for their travel expenses when they are called for follow up assessments.

CONSORT statement
All pregnant women screened for eligibility in this trial will be accounted for and a CONSORT statement will be prepared (http://www.consort-statement.org). Reasons for early withdrawal will be listed for all participants who prematurely discontinued treatment or left the trial.

Table 3 Expected Adverse Events (AE) and Serious Adverse Events (SAE)

| Averse Events                   | Serious Adverse Events     |
|--------------------------------|---------------------------|
| Preterm labour                 | Abortion                  |
| Premature rupture of membranes | Abruptio-placenta         |
| Preeclampsia                   | Intra Uterine Death       |
| Urinary Infection              | Fresh Still Birth         |
|                                | Macerated Still Birth     |
|                                | Congenital anomalies      |
|                                | Neonatal death            |
|                                | Maternal Death            |
The number of participants who were screened eligible but not randomized are presented and the reasons for non-participation (where available) are recorded. A diagram mapping the flow of participants to date is provided (Fig. 1- CONSORT diagram). Recruitment started on 6th Jan 2016 and ended on 31st Aug 2017. We had expected to enroll 1000 women by March 2017 but were delayed by an unexpected capsule shortage, as a result of which we could not recruit for about 4 months. The final number recruited and randomized is 957. About 70% of the enrolled mothers have delivered so far and 15% have completed the trial.

**Statistical analyses**

All the analyses will be performed on the principle of ‘intention to treat’ unless otherwise specified (i.e., we will compare patients in the groups to which they were originally randomly assigned). Statistical analyses will be performed using STATA Version 14.0. We will summarize maternal and household characteristics in the two groups and assess the effectiveness of randomization by comparing these between the groups. Continuous, normally distributed variables will be summarized as means and standard deviations, while skewed variables will be summarized as medians and inter-quartile ranges. Categorical/binary variables will be summarized using proportions. Comparisons on baseline characteristics will also be made between the final study sample and those who were lost to follow up.

For the primary outcome, we will test the unadjusted difference in the mean DASII score at 6 months and 12 months between the two treatment groups using a two-sample t-test. For adjusted analyses, we will consider the DASII score as a continuous variable and use a multiple linear regression model, adjusting for treatment, sex of the child, maternal age, maternal education, socio economic status, birth-weight and other factors which we find out to be significant at baseline comparison. We will adjust for the 6 month DASII score in the model examining the difference in score at 12 months.

![Fig. 1 CONSORT Diagram](image-url)
between the treatment groups using Generalized Estimating Equation (GEE) analyses to account for correlation between the 6 month and 12 month DASII score. The DASII score will also be analysed as a binary variable. DASII score \( \leq 70 \) will be used to defined developmental delay. The unadjusted and adjusted relative risk in the proportion of DASII score (\( \leq 70 \)) at 12 months between DHA and placebo groups will be calculated using a log-binomial regression. In case of convergence issues with the log-binomial model, logistic regressions will be used to conduct the adjusted analyses and adjusted odds ratios will be reported instead of adjusted relative risks.

The differences in weight, length, head circumference, still birth, Apgar score at 1 min & 5 min of the infants at birth will be tested using t-test. Adjusted analyses will be performed using multiple linear regression.

For longitudinal analysis of weight, length and head circumference (i.e. at birth, 1 month, 6 month and 12 month), we will also compare the average growth trajectories of the infants between the treatment and placebo groups using Generalized Estimating Equation (GEE) models. The adjusted analyses will also be performed adjusting for time, maternal weight and height, breast-feeding practices and maternal dietary intake.

Subgroup analyses
The following apriori subgroup analyses will be carried out to evaluate potential heterogeneity of effect:

- Maternal Age (18–20; 21–25; 26–30; 31–35 years)
- BMI categories(< 23; \( \geq 23 \) Kg/m\(^2\))
- Parity
- Gravidae (prima versus multi)
- Dietary patterns (Vegetarian versus non-vegetarian diet)
- Physical activity (Moderate versus sedentary)
- Gestational age (< 32; 30–32; 32–35; 35–38; \( \geq 38 \) weeks)
- Compliance (< 80%, 80–90%, > 90%)
- Duration of supplementation

The results of these subgroup analyses will be treated with caution as this study is not powered for this analyses. In each subgroup analyses, a model will include the subgroup variable along with its interaction with treatment. A test of whether the treatment affects across the levels of the subgroup will be constructed by assessing the significance of the interaction.

Missing data
Sensitivity analyses will be performed using complete case analysis and multiple imputation for missing data to evaluate the potential effect of missing outcomes.

**Discussion**

**Implications for public health and nutrition in India**

In India scientific evidence from iron-folic acid supplementation during pregnancy has been translated to supplementation policy and substantially influenced government actions. More novel dietary interventions which could benefit offspring birth outcomes and enhance later life growth and development need to be explored. This protocol describes a randomised controlled trial comparing the effect of DHA (400 mg/day) with placebo on the neurodevelopment of infants born to pre- and post-natally supplemented mothers. Both animal and human observational studies and few clinical trials point to the possibility that DHA may have a role in the enhancement of offspring neurodevelopment. There have been no randomised controlled trials designed specifically to determine the effect of DHA on neurodevelopment in India. To the best of our knowledge this is the first such randomised controlled trial conducted anywhere in the world which starts supplementation during pregnancy and continues through 6 months post-partum. This trial will lead to enhanced understanding of the role of maternal DHA supplementation on in-utero and early-life cognitive and motor development among their infants. Results from this study will provide the first high quality evidence on whether a prenatal and continued as postnatal DHA supplement improves the neurodevelopment of 1 year old infants born to supplemented mothers.

Although the mechanisms involved are not completely understood, the active properties of DHA are thought to include effects on neuronal development and plasticity, receptor-mediated signaling, changes in membrane fluidity, the formation of second messengers, and/or enhancement of the production of anti-inflammatory lipid mediators due to the availability of DHA as substrate [34, 53].

If successful, we will work to ascertain the best ways to translate the findings to the existing infrastructure and delivery mechanisms of national child development and nutrition programs like the Integrated Child Development Scheme, Anganwadi workers, ASHAs etc.

**Abbreviations**

APGAR: Appearance, Pulse, Grimace, Activity, Respiration; CCDC : Centre for Chronic Disease Control; DHA: Docosahexaenoic Acid; DSMB: Data and Safety Monitoring Board; FW: Field worker; JNMC: Jawaharlal Nehru Medical College; PHF: Prabhakar Kore Hospital; PO: Project Officer; PUFA: Poly unsaturated fatty acids

**Acknowledgements**

We gratefully acknowledge the administrative support from Public Health Foundation of India (PHFI), Gurugram; Centre of Chronic Disease Control (CCDC), Gurugram; and Jawaharlal Nehru Medical College (JNMC), Belgaum, India. We wish to thank our participants and their families. The site project staff, hospital PGs, consultants and other staff members also contributed a lot in the day to day running of this trial.
Funding
This work was supported by the Wellcome Trust/DBT India Alliance Fellowship [IA/CPHE/14/1/501498] awarded to Dr. Shweta Khandelwal (lead author).

Availability of data and materials
The complete datasets are currently being generated for analysis since the study is still being carried out. However, the preliminary data that has been included in this paper is available from the corresponding author on request.

Authors’ contributions
SK wrote the first draft of the manuscript. All other authors especially ADS have provided critical feedback and helped to finalize the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical clearance were obtained from all participating institutions including: Chronic Disease Control (CCDC-IEC-04_2015), Public Health Foundation of India (TRC-IEC-261/15), Jawaharlal Nehru Medical College (MDC/IECHSR/2016–17/A-85) and All India Institute of Medical Sciences (IEC-28/17.11.2015). Written informed consent was obtained from each willing and eligible participant in presence of her close relative or friend.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Public Health Foundation of India, 47, Sector 44, Gurugram, Haryana, India. 2Centre for Chronic Disease Control, Gurugram, India. 3KLEU’s JN Medical College, Belagavi, India. 4Sangath, Delhi, Goa, India. 5Child Development Centre, Prabhakar Kore Hospital, Belagavi, India. 6All India Institute of Medical Sciences, New Delhi, India. 7Research Foundation, KLE University, Belagavi, India. 8Hubert Department of Global Health, Rollins School of Public Health Emory University, Atlanta, USA.

Received: 2 January 2018 Accepted: 18 July 2018
Published online: 04 August 2018

References
1. Stenberg K, et al. Advancing social and economic development by investing in women’s and children’s health: a new global investment framework. Lancet. 2014;383(9925):1333–54.
2. Veera SR, et al. Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review. BMC Pregnancy Childbirth. 2016;16:1–11.
3. Walker SP, et al. Child development: risk factors for adverse outcomes in developing countries. Lancet. 2007;369(9556):145–57.
4. Mendez MA, Adair LS. Severity and timing of stunting in the first two years of life affect performance on cognitive tests in late childhood. J Nutr. 1999;129(6):1555–62.
5. Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. J Nutr. 1995;125(8 Suppl):2233s–41.
6. Grantham-McGregor S, et al. Developmental potential in the first 5 years for children in developing countries. Lancet. 2007;369(9555):60–70.
7. Koblinsky M, et al. Quality maternity care for every woman, everywhere: a call to action. Lancet. 2016;388(10057):2307–20.
8. Nyaradi A, et al. The role of nutrition in children’s neurocognitive development, from pregnancy through childhood. Front Hum Neurosci. 2013;7:97.
9. Al MD, et al. Maternal essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid status. Br J Nutr. 1995;74(1):55–68.
10. Thomas Rajarethnem H, et al. Combined supplementation of choline and docosahexaenoic acid during pregnancy enhances neurodevelopment of fetal hippocampus. Neuroul Res Int. 2017;2017:8748706.
11. Kajabille N, et al. Omega-3 LCPUFA supplement: a nutritional strategy to prevent maternal and neonatal oxidative stress. Mater Child Nutr. 2017;13(2):1–24.
12. Meldrum S, Simmer K. Docosahexaenoic acid and neurodevelopmental outcomes of term infants; Ann Nutr Metab. 2016;69(Suppl 1):22–8.
13. Zhang W, et al. N-3 polynsaturated fatty acids reduce neonatal hypoxic/ischemic brain injury by promoting phosphatidylerine formation and Akt signaling. Stroke. 2015;46(10):2943–50.
14. Makrides M, et al. Four-year follow-up of children born to women in a randomized trial of prenatal DHA supplementation. Jama. 2014;311(17):1802–4.
15. Makrides M, Smithers LC, Gibson RA. Role of long-chain polyunsaturated fatty acids in neurodevelopment and growth. Nestle Nutr Workshop Ser Pediatr Program. 2010;65:123–33. discussion 133-6
16. Birch EE, et al. The DIAMOND (DHA intake and measurement of neural development) study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr. 2010;91(4):848–59.
17. Ranade PS, Rao SS. Maternal diet, LCPUFA status and prematurity in Indian mothers: A cross-sectional study. Functional Foods Health Disease. 2012; 2(11):414–27.
18. Muthayya S, et al. The effect of fish and omega-3 LCPUFA intake on low birth weight in Indian pregnant women. Eur J Clin Nutr. 2009;63(3):340–6.
19. Innis SM. Omega-3 fatty acid biochemistry: perspectives from human nutrition. Mil Med. 2014;179(11 Suppl):82–7.
20. Kilani AS, et al. Long chain polyunsaturated fatty acids in mothers and term babies. J Perinat Med. 2009;37(5):513–8.
21. Dwarkanath P, et al. Polynsaturated fatty acid consumption and concentration among south Indian women during pregnancy. Asia Pac J Clin Nutr. 2005;18(3):389–94.
22. Simopoulos AP. The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease. Asia Pac J Clin Nutr. 2009;18(3):389–94.
23. Mani I, Kurpad AV. Fats & fatty acids in Indian diets: time for serious introspection. Indian J Med Res. 2016;144(4):S07–14.
24. Rathod R, Kale A, Joshi S. Novel insights into the effect of vitamin B12 and omega-3 fatty acids on brain function. J Biomed Sci. 2016;23
25. Laurrent L, et al. DHA Effects in Brain Development and Function. Nutrients. 2016;8(1):1–17.
26. Madhika M, et al. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. Jama. 2010;304(15):1675–83.
27. Makrides M, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. Jama. 2009; 301(2):175–82.
28. Ramakrishnan U, Imhoff-Kunsch B, DiGrolamo AM. Role of docosahexaenoic acid in maternal and child mental health.1234 Am J Clin Nutr. 2009;99(9):598s–62s.
29. Ramakrishnan U, et al. Prenatal supplementation with DHA improves attention at 5 y of age: a randomized controlled trial. Am J Clin Nutr. 2016; 104(4):1075–82.
30. Hibbelin JR, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007;369(9561):578–85.
31. Olsen SF, et al. Duration of pregnancy in relation to seafood intake during early and mid pregnancy: prospective cohort. Eur J Epidemiol. 2006;21(10):749–58.
32. Olsen SF, Secher NJ. Low consumption of seafood in early pregnancy as a risk factor for preterm delivery: prospective cohort study. BMJ. 2002;324(7335):447.
33. Olsen SF, et al. Frequency of seafood intake in pregnancy as a determinant of birth weight: evidence for a dose dependent relationship. J Epidemiol Community Health. 1993;47(6):436–40.
34. Rogers LK, Valentine CJ, Keim SA. DHA supplementation: current implications in pregnancy and childhood. Pharmacol Res. 2013;70(1):13–9.
35. Peter S, Chopra S, Jacob JJ. A fish a day, keeps the cardiologist away! – a review of the effect of omega-3 fatty acids in the cardiovascular system. Indian J Endocrinol Metab. 2013;17(5):422–9.
36. Hooper L, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004(4):CD003177.
37. National Institute of Child Health and Human Development Early Child Care Research Network. Duration and developmental timing of poverty and children’s cognitive and social development from birth through third grade. Child Dev. 2005;76(4):795–810.
38. Pusceddu MM, et al. N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology. Int J Neuropsychopharmacol. 2016;19(12):1–23.

39. Black MM, et al. Early childhood development coming of age: science through the life course. Lancet. 2017;389(10064):77–90.

40. Chen GC, et al. N-3 long-chain polyunsaturated fatty acids and risk of all- cause mortality among general populations: a meta-analysis. Sci Rep. 2016;6:28165.

41. Del Gobbo LC, et al. Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med. 2016;176(8):1155–66.

42. Gianni ML, et al. Randomized outcome trial of nutrient-enriched formula and neurodevelopmental outcome in preterm infants. BMC Pediatr. 2014;14:74.

43. Bhave A, Bhargava R, Kumar R. Correlation between developmental quotients (DASIII) and social quotient (Malin’s VSMS) in Indian children aged 6 months to 2 years. J Paediatr Child Health. 2011;47(3):87–91.

44. Phatak AT, Khurana B. Baroda development screening test for infants. Indian Pediatrics. 1991;28(1):31–7.

45. Bhave A, Bhargava R, Kumar R. Development and validation of a new Lucknow development screen for Indian children aged 6 months to 2 years. J Child Neurol. 2010;25(1):57–60.

46. Godbole K, Barve S, Chaudhari S. Early predictors of neurodevelopmental outcome in high risk infants. Indian Pediatr. 1997;34(6):491–5.

47. Junega M, et al. Ages and stages questionnaire as a screening tool for developmental delay in Indian children. Indian Pediatr. 2012;49(6):457–61.

48. Mukhopadhyay K, et al. Neurodevelopmental and behavioral outcome of very low birth weight babies at corrected age of 2 years. Indian J Pediatr. 2010;77(9):963–7.

49. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986;27(1):114–20.

50. Elchalal U, et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstet Gynecol. 2000;182(1 Pt 1):227–32.

51. Miller EM, et al. Field and laboratory methods in human milk research. Am J Hum Biol. 2013;25(1):1–11.

52. Christie WW. A simple procedure for rapid transmethylation of glycerolipids and cholesterol esters. J Lipid Res. 1982;23(7):1072–5.

53. Harris WS, Baack ML. Beyond building better brains: bridging the docosahexaenoic acid (DHA) gap of prematurity. J Perinatol. official journal of the California Perinatal Association. 2015;35(1):1–7.